modest benefit, serious potential harms, high cost
Canada has approved lecanemab, a drug targeting the amyloid buildup associated with early Alzheimer's disease, yet its arrival is shadowed by a difficult truth: the benefits are modest, the risks are genuine, and the costs are prohibitive for most. Medical analysts writing in the Canadian Medical Association Journal remind us that regulatory approval and clinical wisdom are not always the same thing — that the distance between slowing a disease and improving a life is vast and morally significant. In a condition that touches millions of families, the temptation to equate any progress with sufficient progress deserves careful, patient scrutiny.
- Canada has approved lecanemab, but the drug's own evidence base tells a story of small gains and real dangers — brain swelling and bleeding are documented risks, not theoretical ones.
- At $35,000 to $40,000 per year, with no provincial insurance coverage committed, the treatment is financially out of reach for the majority of patients who might qualify.
- Before a single infusion, patients must undergo either a PET scan or a lumbar puncture to confirm amyloid presence, then commit to regular IV treatments and frequent MRI monitoring — a logistical burden that is itself a form of cost.
- Geriatricians and clinical analysts are pushing back against reflexive optimism, arguing that the gap between slowing cognitive decline and actually improving quality of life or independence remains unresolved by current evidence.
- The emerging consensus is not rejection but restraint: individualized shared decision-making, where some patients may reasonably choose to wait for stronger evidence rather than accept uncertain benefits at significant personal risk and expense.
Canada's approval of lecanemab for early Alzheimer's disease has arrived with a complicated asterisk. A new analysis in the Canadian Medical Association Journal, led by geriatrician Dr. Sharon Straus of Unity Health Toronto, examines what the evidence actually shows — and finds that the clinical benefits, while real, are modest at best. The drug targets amyloid, the protein that accumulates in Alzheimer's-affected brains, and may slow cognitive decline. But whether it meaningfully improves how patients live — their independence, their quality of life, the burden on caregivers — remains genuinely uncertain. That distinction matters enormously.
The practical landscape is daunting. Treatment runs $35,000 to $40,000 annually, with no confirmed public insurance coverage across Canada's provinces and territories, leaving most patients to bear the cost themselves. Accessing the drug also requires specialized diagnostic testing to confirm amyloid presence, followed by regular intravenous infusions and frequent MRI monitoring to catch potential complications — including brain swelling and small bleeds that can occur as the drug clears amyloid deposits.
Straus and her colleagues argue that this combination of modest benefit, documented risk, intensive monitoring, and steep cost demands something more than a standard clinical recommendation. They advocate for genuine shared decision-making — conversations in which individual patients weigh what matters most to them. Some may find even a small delay in progression worth the burden. Others may reasonably choose to wait for stronger evidence. To support these conversations, the authors have developed a clinical decision-making tool. Lecanemab is not a cure, and its approval is not a clear victory. It is a narrow, costly, risk-laden option — and the caution surrounding it is as warranted as the approval itself.
Canada's health regulators have approved lecanemab for early Alzheimer's disease, but the drug arrives with a complicated reality: the clinical gains are small, the risks are real, and the price tag is steep. A new analysis in the Canadian Medical Association Journal cuts through the cautious optimism surrounding the approval to lay out what doctors and patients actually need to know before deciding whether treatment makes sense.
Lecanemab works by targeting amyloid, a protein that accumulates in the brains of people with Alzheimer's. The drug's job is to clear that buildup, potentially slowing cognitive decline. But here's where the enthusiasm hits a wall. Dr. Sharon Straus, a geriatrician at Unity Health Toronto and professor at the University of Toronto, and her colleagues examined the evidence and found that while lecanemab does show some benefit, it is modest at best. The drug may delay disease progression, but whether it actually improves how people live—their quality of life, their independence, the burden on those caring for them—remains genuinely uncertain. That gap between slowing decline and improving life is not a small distinction.
The practical barriers are substantial. Treatment costs between $35,000 and $40,000 per year, and Canada's provinces and territories have not committed to covering it through public insurance. Most patients would pay out of pocket, a barrier that immediately excludes many. Beyond cost, the treatment itself demands significant resources. Patients need specialized diagnostic testing—either a PET scan or a lumbar puncture to confirm amyloid in the brain—before they can even start. Once approved, they receive regular intravenous infusions and must undergo frequent MRI scans to monitor for complications. The drug can cause brain swelling and small bleeds as it clears amyloid, side effects that require vigilant watching.
Straus and her colleagues argue that this constellation of factors—modest benefit, serious potential harms, high cost, intensive monitoring—demands a different kind of conversation between doctors and patients. They call it shared decision-making, and they mean something specific: not a doctor recommending treatment, but a genuine exploration of what matters to each individual. Some patients, they note, may place high value on even a small delay in disease progression and may be willing to accept the risks, the monitoring burden, and the financial cost. For others, waiting for more evidence while the disease progresses slowly may be the more reasonable choice. There is no single right answer.
The authors have developed a tool to help clinicians navigate these conversations, recognizing that the decision to start lecanemab should be tailored to each person's values, circumstances, and tolerance for uncertainty. In a disease as burdensome as Alzheimer's—for patients and families alike—the temptation to reach for any approved treatment is understandable. But lecanemab is not a cure, and it is not a clear win. It is a drug with a narrow window of benefit, real risks, and a price that most Canadians cannot easily afford. The approval is real. The caution is warranted.
Notable Quotes
Clinical benefits are modest at best, with uncertain impacts on quality of life, independence and caregiver burden.— Dr. Sharon Straus, geriatrician at Unity Health Toronto
The decision to initiate lecanemab should be individualized. Some patients may choose to proceed and accept the risks, while in other cases deferring treatment pending further evidence may be reasonable.— Dr. Sharon Straus and co-authors
The Hearth Conversation Another angle on the story
Why does a drug that's been approved still need this kind of careful discussion? Shouldn't approval mean it's ready to use?
Approval means it works better than placebo and meets safety thresholds. It doesn't mean it's right for everyone, or that the benefit is large enough to outweigh the burden for a particular person.
What's the actual difference lecanemab makes? How much slower does the disease progress?
That's the hard part. The clinical trials show modest slowing, but we don't have clear data on whether patients actually feel better, stay independent longer, or whether caregivers experience less burden. The benefit exists, but it's not transformative.
And the brain swelling and bleeding—how common are those?
They're documented risks, but not universal. Still, they require monitoring with MRI scans, which adds cost, time, and anxiety. For someone already facing cognitive decline, that's not trivial.
So who should take it?
Someone who values even a small delay in decline enough to accept $35,000 to $40,000 yearly out of pocket, plus the monitoring and the risks. That's a specific person with specific values. Many won't fit that picture.
What happens to people who can't afford it?
They don't get it. And that's a real inequity, because the people most likely to benefit are older, often on fixed incomes. The drug exists, but it's not accessible to most.